> Detailanzeige

Brivio, Erica; Locatelli, Franco; Lopez-Yurda, Marta; Malone, Andrea; Díaz-de-Heredia, Cristina; Bielorai, Bella; Rossig, Claudia; van der Velden, Vincent H. J.; Ammerlaan, Anneke C. J.; Thano, Adriana; van der Sluis, Inge M.; den Boer, Monique L.; Chen, Ying; Sleight, Barbara; Brethon, Benoit; Nysom, Karsten; Sramkova, Lucie; Øra, Ingrid; Vinti, Luciana; Chen-Santel, Christiane; Zwaan, Christian Michel

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
  • Beteiligte: Brivio, Erica; Locatelli, Franco; Lopez-Yurda, Marta; Malone, Andrea; Díaz-de-Heredia, Cristina; Bielorai, Bella; Rossig, Claudia; van der Velden, Vincent H. J.; Ammerlaan, Anneke C. J.; Thano, Adriana; van der Sluis, Inge M.; den Boer, Monique L.; Chen, Ying; Sleight, Barbara; Brethon, Benoit; Nysom, Karsten; Sramkova, Lucie; Øra, Ingrid; Vinti, Luciana; Chen-Santel, Christiane; Zwaan, Christian Michel
  • Erschienen: American Society of Hematology, 2021
  • Erschienen in: Blood
  • Sprache: Englisch
  • DOI: 10.1182/blood.2020007848
  • ISSN: 1528-0020; 0006-4971
  • Schlagwörter: Cell Biology ; Hematology ; Immunology ; Biochemistry
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:p>This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia (ALL). Patients (age ≥1 year or &amp;lt;18 years) received 3 doses of InO (days 1, 8, and 15) per course. Dose escalation was based on dose-limiting toxicities (DLTs) during course 1. Dose level 1 (DL1) was 1.4 mg/m2 (0.6, 0.4, 0.4 mg/m2) and DL2 was 1.8 mg/m2 (0.8, 0.5, 0.5 mg/m2). Secondary end points included safety, antileukemic activity, and pharmacokinetics. Twenty-five patients (23 evaluable for DLTs) were enrolled. In course 1, the first cohort had 1 of 6 (DL1) and 2 of 5 (DL2) patients who experienced DLTs; subsequent review considered DL2 DLTs to be non–dose-limiting. Dose was de-escalated to DL1 while awaiting protocol amendment to re-evaluate DL2 in a second cohort, in which 0 of 6 (DL1) and 1 of 6 (DL2) patients had a DLT. Twenty-three patients experienced grade 3 to 4 adverse events; hepatic sinusoidal obstruction syndrome was reported in 2 patients after subsequent chemotherapy. Overall response rate after course 1 was 80% (95% confidence interval [CI], 59% to 93%) (20 of 25 patients; DL1: 75% [95% CI, 43% to 95%], DL2: 85% [95% CI, 55% to 98%]). Of the responders, 84% (95% CI, 60% to 97%) achieved minimal residual disease (MRD)-negative complete response, and 12-month overall survival was 40% (95% CI, 25% to 66%). Nine patients received hematopoietic stem cell transplantation or chimeric antigen receptor T cells after InO. InO median maximum concentrations were comparable to simulated adult concentrations. InO was well tolerated, demonstrating antileukemic activity in heavily pretreated children with CD22+ R/R ALL. RP2D was established as 1.8 mg/m2 per course, as in adults. This trial was registered at https://www.clinicaltrialsregister.eu as EUDRA-CT 2016-000227-71.</jats:p>
  • Zugangsstatus: Freier Zugang